Impact of High Dose Acyclovir Prophylaxis for the Prevention of Cytomegalovirus Reactivation after Pediatric Allogeneic Stem Cell Transplant
In the absence of cytomegalovirus (CMV) prophylaxis (ppx), CMV DNAemia occurs in up to 70% of allogeneic hematopoietic cell transplants (HCT). Post-HCT CMV infection can be life-threatening. Letermovir is routine for CMV ppx adult HCT, but not FDA approved for
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Susie Long, Abbey Krebs, Beth Thielen, Christen L. Ebens Tags: 636 Source Type: research
More News: Acyclovir | Biology | Cytomegalovirus | Hematology | Pediatrics | Stem Cell Therapy | Stem Cells | Transplants | Zovirax